Table 2:
Select ongoing clinical trials using novel agents or investigational combinations of approved therapies in FL.
| Treatment | Targets | FL Patients | Phase | Trial Number |
|---|---|---|---|---|
| Venetoclax + Oral AZA (CC-486) + Obinutuzumab | BCL2, epigenetic modulation, CD20 | Frontline FL | 1/2 | NCT04722601 |
|
PrE0403: Venetoclax + Obinutuzumab + Bendamustine |
BCL2, CD20, DNA damage | Frontline FL | 2 | NCT03113422 |
|
LEVERAGE: Lenalidomide + Venetoclax + Obinutuzumab |
Immunomodulation, BCL2, CD20 | Frontline FL | 1/2 | NCT03980171 |
| Acalabrutinib + Obinutuzumab | BTK, CD20 | Frontline FL | 2 | NCT04883437 |
|
SWOG S1608 (Randomized): 1: Obinutuzumab + Umbralisib 2. Obinutuzumab + Lenalidomide 3. BO or O-CHOP |
CD20, PI3K (delta, CK1-epsilon), immunomodulation, DNA damage | RR-FL (early relapse) | 2 | NCT03269669 |
| Umbralisib + Ublituximab + Lenalidomide | PI3K (delta, CK1-epsilon), CD20, immunomodulation | RR-FL | 1 | NCT04635683 |
|
CITADEL-302 (Randomized): 1. Parsaclisib + Rituximab or Obinutuzumab 2. Placebo + Rituximab or Obinutuzumab |
PI3K delta | RR-FL | 3 | NCT04796922 |
|
COASTAL (Randomized): 1. Zandelisib + Rituximab 2. BR or R-CHOP |
PI3K delta, CD20, DNA damage | RR-FL | 3 | NCT04745832 |
|
Randomized: 1. Tazemetostat + Lenalidomide + Rituximab 2. Placebo + Lenalidomide + Rituximab |
EZH2, immunomodulation, CD20 | RR-FL | 3 | NCT04224493 |
|
SYMPHONY-2: Tazemetostat + Rituximab |
EZH2, CD20 | RR-FL | 2 | NCT04762160 |
|
InMIND (Randomized): 1. Tafasitamab + Rituximab + Lenalidomide 2. Placebo + Rituximab + Lenalidomide |
CD19, CD20, immunomodulation | RR-FL | 3 | NCT04680052 |
|
LOTIS 6 (Randomized): 1. Loncastuximab tesirine 2. Idelalisib |
CD19 ADC, PI3K (delta) | RR-FL | 2 | NCT04699461 |
| Loncastuximab tesirine + Venetoclax | CD19 ADC, BCL2 | RR-FL | 1 | NCT05053659 |
|
TRASNCEND FL: Lisocabtagene maraleucel |
CD19 CAR T-cell | RR-FL | 2 | NCT04245839 |
|
VENOM: Venetoclax + Obinutuzumab + Magrolimab |
BCL2, CD20, CD47 | RR-FL | 1 | NCT04599634 |
| Magrolimab + Rituximab | CD47, CD20 | RR-FL | 2 | NCT02953509 |
| 1. Rituximab+ Pembrolizumab 2. Rituximab+ Pembrolizumab + Lenalidomide |
CD20, PD1, immunomodulation | RR-FL | 2 | NCT02446457 |
| Pembrolizumab + Rituximab or Obinutuzumab | PD1, CD20 | RR-FL | 2 | NCT03401853 |
| Ibrutinib + Nivolumab | BTK, PD1 | RR-FL | 1/2 | NCT02329847 |
ADC = antibody drug conjugate, AZA = azacitidine, BTK = Bruton’s tyrosine kinase, BO = bendamustine, obinutuzumab, CAR = chimeric antigen receptor, CK= casein kinase, FL = follicular lymphoma, O-CHOP = obinutuzumab, cyclophosphamide, doxorubicin, vincristine, and prednisone, PI3K = phosphoinositide 3-kinase, RR-FL = relapsed/refractory follicular lymphoma.